Ovarian Cancer

Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.

Latest Discoveries

Luveltamab tazevibulin showed responses in platinum-resistant ovarian cancer in dose-optimization data; the trial was later terminated

Evidence stage: Emerging ClinicalRegulatory status: Investigational
Cancer type
Ovarian Cancer
Published
August 13, 2026

In the dose-optimization portion of the now-terminated phase 2/3 REFRaME-O1 trial, the antibody-drug conjugate luveltamab tazevibulin produced objective responses in patients with platinum-resistant ovarian cancer expressing folate receptor alpha, at…

Primary source cited

Last reviewed

FDA approves the first immunotherapy regimen for platinum-resistant ovarian cancer with a proven survival benefit

Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
Cancer type
Ovarian Cancer
Published
August 13, 2026

In the randomized, phase 3 ENGOT-ov65/KEYNOTE-B96 trial, adding pembrolizumab to paclitaxel chemotherapy significantly improved BOTH progression-free survival (8.3 vs 7.2 months) AND overall survival (18.2 vs 14.0 months) in patients…

Primary source cited

Last reviewed

Major Advances

Luveltamab tazevibulin showed responses in platinum-resistant ovarian cancer in dose-optimization data; the trial was later terminated

Evidence stage: Emerging ClinicalRegulatory status: Investigational
Cancer type
Ovarian Cancer
Published
August 13, 2026

In the dose-optimization portion of the now-terminated phase 2/3 REFRaME-O1 trial, the antibody-drug conjugate luveltamab tazevibulin produced objective responses in patients with platinum-resistant ovarian cancer expressing folate receptor alpha, at…

Primary source cited

Last reviewed

FDA approves the first immunotherapy regimen for platinum-resistant ovarian cancer with a proven survival benefit

Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
Cancer type
Ovarian Cancer
Published
August 13, 2026

In the randomized, phase 3 ENGOT-ov65/KEYNOTE-B96 trial, adding pembrolizumab to paclitaxel chemotherapy significantly improved BOTH progression-free survival (8.3 vs 7.2 months) AND overall survival (18.2 vs 14.0 months) in patients…

Primary source cited

Last reviewed

Clinical Trials

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Luveltamab tazevibulin showed responses in platinum-resistant ovarian cancer in dose-optimization data; the trial was later terminated

Regulatory status: InvestigationalEvidence stage: Emerging Clinical
Cancer type
Ovarian Cancer
Trial identifier
NCT05870748
View trial details
Study design
Non-randomized trial
Population
Adults with recurrent, platinum-resistant ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing folate receptor alpha (FRα), who received 1-3 prior lines of therapy, enrolled in the dose-optimization portion of a phase 2/3 trial that has since been terminated before its planned randomized phase 3 portion began (see correction_note). Efficacy figures here are from the 25-patient cohort receiving the dosing regimen originally selected for further study.
Last reviewed
2026-08-13

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Primary evidence supporting this story

Eligibility varies — review trial criteria.

FDA Approvals

Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.

FDA approves the first immunotherapy regimen for platinum-resistant ovarian cancer with a proven survival benefit

Regulatory status: FDA ApprovedEvidence stage: Later-Stage Human
Cancer type
Ovarian Cancer
Population
Adults with platinum-resistant, PD-L1-positive (CPS >=1) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who had received one to two prior lines of systemic therapy, randomized to pembrolizumab plus paclitaxel (+/- bevacizumab) or placebo plus paclitaxel (+/- bevacizumab), in the randomized, double-blind, phase 3 ENGOT-ov65/KEYNOTE-B96 trial conducted at 187 sites in 25 countries.
View approval details
Last reviewed
2026-08-13

Regulatory status by jurisdiction

United States (FDA)

Status
FDA-approved for the exact stated cancer/use
Indication
Adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS >=1), who have received one to two prior lines of systemic therapy.
Biomarker requirement
PD-L1 CPS >=1 (PD-L1 IHC 22C3 pharmDx)
Decision date
2026-02-10
Source
Regulator record (opens in a new tab)

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Applies to the exact indication stated.

Refine your search

Related resources

Trusted resources: official cancer information

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.